Effect of Descurainia sophia (L.) Webb ex Prantl on Adult Functional Constipation: A Prospective Pilot Study

Journal of Evidence-Based Complementary and Alternative Medicine

Volumn 22, Issue 4, 2017, Pages 646-651

  Choopani, Rasool ^a   Ghourchian, Anahita ^a   Hajimehdipoor, Homa ^a   Kamalinejad, Mohammad ^a   Ghourchian, Fatemeh ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bristol Stool Form Scale; complete spontaneous bowel movements per week; Descurainia sophia; functional constipation; PAC SYM

Indexed keywords

EID: 85039728447     PISSN: 21565872     EISSN: None     Source Type: Journal    
DOI: 10.1177/2156587217703018     Document Type: Article

References (35)

1. Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol. 2008;8:5.
2. Pare P, Ferrazzi S, Thompson W, Irvine E, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001;96:3130–3137.
3. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99:750–759.
4. Garrigues V, Gálvez C, Ortiz V, Ponce M, Nos P, Ponce J. Prevalence of constipation: agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a population-based survey in Spain. Am J Epidemiol. 2004;159:520–526.
5. Zhao YF, Ma XQ, Wang R. Epidemiology of functional constipation and comparison with constipation-predominant irritable bowel syndrome: the Systematic Investigation of Gastrointestinal Diseases in China (SILC). Aliment Pharmacol Ther. 2011;34:1020–1029.
6. Zahedi MJ, Moghadam SD, Abbasi MHB, Mirzaei SMS. The assessment prevalence of functional constipation and associated factors in adults: a community-based study from Kerman, Southeast, Iran (2011-2012). Govaresh. 2014;19:95–101.
7. Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders, Functional Constipation. http://www.romecriteria.org/assets/pdf/19_RomeIII_apA_885-898.pdf. Accessed January 30, 2016.
8. Vlieger AM, Benninga MA. Complementary and alternative treatments for motility and sensory disorders. In: Faure C, Di Lorenzo C, Thapar N, eds. Pediatric Neurogastroenterology: Gastrointestinal Motility and Functional Disorders in Children. Totowa, NJ: Humana Press; 2013:481–491.
9. Noras MR, Kiani MA. Viewpoints of traditional Iranian medicine (TIM) about etiology of pediatric constipation. Int J Pediatr. 2014;2:89–92.
10. Hamedi S, Jokar A, Abbasian A. viewpoints of Iranian traditional medicine (ITM) about etiology of constipation. J Gastrointest Dig Syst. 2012;S8:005. doi:10.4172/2161-069X.S8-005.
11. Hashem Dabaghian F, Taghavi Shirazi M, Amini Behbahani F, Shojaee A. Interventions of Iranian traditional medicine for constipation during pregnancy. J Med Plants. 2015;53:58–68.
12. Khan M, Wang N. Descurainia sophia (L.): a weed with multiple medicinal uses. Punjab Univ J Zool. 2012;27:45–51.
13. Nimrouzi M, Zarshenas MM. Phytochemical and pharmacological aspects of Descurainia sophia (L.) Webb ex Prantl: modern and traditional applications. Avicenna J Phytomed. 2016;63:266–272.
14. Zarshenas MM, Petramfar P, Firoozabadi A, Moein MR, Mohagheghzadeh A. Types of headache and those remedies in traditional Persian medicine. Pharmacogn Rev. 2013;7(13):17–26.
15. Khorasani MA. Makhzan-al-Advieh (The Storehouse of Medicaments). Tehran, Iran: Bavardaran Press; 2001.
16. Ma MF, Lu WH, Li J. Experimental research on pharmacology and acute toxicology of Descurainia sophia (L.) Webb ex Prantl processed. Chin Arch Tradit Chin Med. 2008;8:095.
17. Nimrouzi M, Sadeghpour O, Imanieh MH. Flixweed vs. polyethylene glycol in the treatment of childhood functional constipation: a randomized clinical trial. Iran J Pediatr. 2015;25(2):e425.
18. Pasalar M, Bagheri Lankarani K, Mehrabani D, Tolidei H, Naseri M. The effect of Descurainia sophia L. and Prunus domestica L. in prevention of constipation among Iranian Hajj Pilgrims, Saudi Arabia. Res J Pharm Biol Chem Sci. 2013;4:1195–1204.
19. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377–1390.
20. Frank L, Kleinman L, Farup C, Taylor L, Miner P. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol. 1999;34:870–877.
21. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
22. World Health Organization. BMI classification. http://apps.who.int/bmi/index.jsp. Accessed January 26, 2016.
23. Heydari ST, Ayatollahi SMT, Zare N. Diagnostic value of bioelectrical impedance analysis versus body mass index for detection of obesity among students. Asian J Sports Med. 2011;2(2):68–74.
24. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.
25. Mohamed NH, Mahrous AE. Chemical constituents of Descurainia sophia L. and its biological activity. Rec Nat Prod. 2009;3:58–67.
26. Sun K, Li X, Liu JM, Wang JH, Li W, Sha Y. A novel sulphur glycoside from the seeds of Descurainia sophia (L.). J Asian Nat Prod Res. 2005;7:853–856.
27. Karami H, Khademloo M, Niari P. Polyethylene glycol versus paraffin for the treatment of childhood functional constipation. Iran J Pediatr. 2009;19:255–261.
28. Wang Y, Wang B, Jiang X. Polyethylene glycol 4000 treatment for children with constipation: a randomized comparative multicenter study. Exp Ther Med. 2012;3:853–856.
29. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;(7):CD007570. doi:10.1002/14651858.CD007570.pub2.
30. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–2354.
31. Quigley E, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315–328.
32. Tack J, Van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58:357–365.
33. Rao S, Lembo AJ, Shiff SJ. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714–1724.
34. Lewis S, Heaton K. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–924.
35. Riegler G, Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Tech Coloproctol. 2001;5:163–164.